For BMS, Onglyza Disappoints And Health Care Reform Takes A Toll
This article was originally published in The Pink Sheet Daily
Executive Summary
The health care reform law, which will lower Bristol-Myers Squibb's sales by $350 million to $400 million this year, led the firm to revise earnings guidance.